We further demonstrate that murine SCLC tumors were highly sensitive to ATR- and CHK1 inhibitors, while KrasG12D-driven murine lung adenocarcinomas were resistant against these compounds and displayed continued growth under therapy. This evidence concerns the gene CHEK1 and small cell lung carcinoma.